2008 - Review: Hemoglobin-based blood substitutes increase mortality and myocardial infarction in surgical, trauma, and stroke settings

Kao, Lillian S.; Gallus, Alexander
November 2008
ACP Journal Club;11/18/2008, Vol. 149 Issue 5, p2
Academic Journal
The article presents information on a study conducted to find out if hemoglobin-based blood substitutes (HBBSs) increase risk for myocardial infarction (MI) and death more than usual care in surgical trauma. Meta-analysis conducted showed that HBBSs increased risk for mortality and MI more than usual care in patients who had surgery, trauma, or stroke. It is stated that the limitations of this meta-analysis included lack of rigorous assessment of unpublished trials.


Related Articles

  • Hemoglobin-based blood substitutes increased risk for death, MI. Jacob, Harry S. // Cardiology Today;Jul2008, Vol. 11 Issue 7, p45 

    The article presents a study which revealed that the risk for death and myocardial infarction linked to hemoglobin-based blood substitutes has increased 30%. A meta-analysis study was conducted by researchers from Maryland and Washington, D.C. on stroke, trauma and surgical patients. For risk...

  • Hemoglobin-based blood substitutes: increased risk and no clinical benefit. Adams, Stacey L. // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p1 

    The article reports that according to data published in the "Journal of the American Medical Association," hemoglobin-based blood substitutes (HBBS) may increase the risk for myocardial infarction (MI) 2.7-fold. HBBS products have also been associated with a 30% increased risk for death,...

  • FRONTLINE.  // Women's Health Advisor;Sep2014, Vol. 18 Issue 9, p2 

    The article presents information on several research results related to medicine. A study found that taking niacin does not lower cardiovascular events risk like heart attack and stroke. Another study found that women who didn't consume caffeine were less likely to have postmenopausal symptoms...

  • Hemoglobin-based blood substitutes increased risk for death, MI. Jacob, Harry S. // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p28 

    The article focuses on the findings of researchers from Maryland and Washington, D.C. which showed that during the last decade, the risk for death and myocardial infarction associated with hemoglobin-based blood substitutes has increased 30 percent. A meta-analysis was conducted to examine the...

  • 2008 - Review: Statins are effective for prevention of cardiovascular events in patients without coronary heart disease. McAlister, Finlay A. // ACP Journal Club;4/21/2009, Vol. 150 Issue 4, p3 

    The article discusses whether statins are effective for primary prevention of cardiovascular (CV) events. Medical studies comparing statins with placebo, standard therapy, or no treatment for primary prevention were taken into account. Meta-analysis showed that statins reduces all-cause...

  • Lifetime Risks of Cardiovascular Disease. Berry, Jarett D.; Dyer, Alan; Cai, Xuan; Garside, Daniel B.; Ning, Hongyan; Thomas, Avis; Greenland, Philip; Van Horn, Linda; Tracy, Russell P.; Lloyd-Jones, Donald M. // New England Journal of Medicine;1/26/2012, Vol. 366 Issue 4, p321 

    Background: The lifetime risks of cardiovascular disease have not been reported across the age spectrum in black adults and white adults. Methods: We conducted a meta-analysis at the individual level using data from 18 cohort studies involving a total of 257,384 black men and women and white men...

  • Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. Boffetta, Paolo; Straif, Kurt // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/29/2009, Vol. 339 Issue 7719, p502 

    The article discusses a study which investigated the use of smokeless tobacco products in Europe and North America and the risk of myocardial infarction and stroke. A meta-analysis of observational studies from Europe and North America was conducted by the authors using electronic databases and...

  • Vioxx should have been withdrawn years earlier.  // Reactions Weekly;11/13/2004, Issue 1027, p5 

    Discusses research being done on the level of risk of myocardial infarction associated with rofecoxib use. Reference to a study by P. Jüni et al, published in the November 2004 issue of "Lancet"; Results of the meta-analysis of clinical trials concerning rofecoxib in patients with chronic...

  • Improvement in Prediction of Coronary Heart Disease Risk over Conventional Risk Factors Using SNPs Identified in Genome-Wide Association Studies. Bolton, Jennifer L.; Stewart, Marlene C. W.; Wilson, James F.; Anderson, Niall; Price, Jackie F. // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Objective: We examined whether a panel of SNPs, systematically selected from genome-wide association studies (GWAS), could improve risk prediction of coronary heart disease (CHD), over-and-above conventional risk factors. These SNPs have already demonstrated reproducible associations with CHD;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics